Description

Merck Acquisition Shock: Is The $6B Terns Takeover A Game-Changer?

Merck & Co. is reportedly in advanced talks to acquire Terns Pharmaceuticals in an all-cash transaction valued at about $6 billion, according to the text provided in this conversation. The reported interest arrives at a highly consequential moment for Merck. Management has been explicit that the company is reshaping its portfolio ahead of Keytruda’s expected loss of exclusivity, while also using disciplined business development to add late-stage and strategically relevant assets. On its February 2026 earnings call, Merck emphasized that its portfolio transformation is already underway, highlighted acquisitions such as Verona Pharma and Cidara Therapeutics, and reiterated that external innovation remains a priority where science, unmet need, and value creation align. Against that backdrop, Terns appears to fit a larger strategic pattern rather than a one-off bet.